0001493152-22-007206.txt : 20220317
0001493152-22-007206.hdr.sgml : 20220317
20220317212746
ACCESSION NUMBER: 0001493152-22-007206
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20220317
DATE AS OF CHANGE: 20220317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paulsen Gisela
CENTRAL INDEX KEY: 0001807104
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 22750878
MAIL ADDRESS:
STREET 1: 5505 ENDEAVOR LANE
CITY: MADISON
STATE: WI
ZIP: 53719
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncocyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-409-7600
MAIL ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20200213
FORMER COMPANY:
FORMER CONFORMED NAME: Oncocyte Corp
DATE OF NAME CHANGE: 20200205
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20150513
4
1
ownership.xml
X0306
4
2022-03-15
0
0001642380
Oncocyte Corp
OCX
0001807104
Paulsen Gisela
15 CUSHING
IRVINE
CA
92618
0
1
0
0
Chief Operating Officer
Common Stock, no par value
2022-03-17
4
P
0
16500
1.198
A
16500
D
Option to Purchase Common Stock
1.150
2022-03-15
4
A
0
125000
0
A
2032-03-15
Common Stock
125000
125000
D
Option to Purchase Common Stock
1.150
2022-03-15
4
A
0
125000
0
A
2032-03-15
Common Stock
125000
125000
D
The price of $1.198 per share represents a weighted average of prices ranging from $1.180 to $1.200 per share. The reporting person undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price
25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
/s/ Gisela Paulsen
2022-03-17